Cancel anytime
Boston Scientific Corp (BSX)BSX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2024: BSX (4-star) is a STRONG-BUY. BUY since 45 days. Profits (6.94%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Regular Buy |
Historic Profit: 41.83% | Upturn Advisory Performance 3 | Avg. Invested days: 67 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 10/24/2024 |
Type: Stock | Today’s Advisory: Regular Buy |
Historic Profit: 41.83% | Avg. Invested days: 67 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 10/24/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 133.13B USD |
Price to earnings Ratio 74.65 | 1Y Target Price 97 |
Dividends yield (FY) - | Basic EPS (TTM) 1.21 |
Volume (30-day avg) 6049784 | Beta 0.8 |
52 Weeks Range 53.93 - 91.08 | Updated Date 11/19/2024 |
Company Size Large-Cap Stock | Market Capitalization 133.13B USD | Price to earnings Ratio 74.65 | 1Y Target Price 97 |
Dividends yield (FY) - | Basic EPS (TTM) 1.21 | Volume (30-day avg) 6049784 | Beta 0.8 |
52 Weeks Range 53.93 - 91.08 | Updated Date 11/19/2024 |
Earnings Date
Report Date 2024-10-23 | When BeforeMarket |
Estimate 0.59 | Actual 0.63 |
Report Date 2024-10-23 | When BeforeMarket | Estimate 0.59 | Actual 0.63 |
Profitability
Profit Margin 11.26% | Operating Margin (TTM) 17.06% |
Management Effectiveness
Return on Assets (TTM) 4.9% | Return on Equity (TTM) 8.92% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE 74.65 | Forward PE 32.26 |
Enterprise Value 141886836720 | Price to Sales(TTM) 8.37 |
Enterprise Value to Revenue 8.92 | Enterprise Value to EBITDA 38.08 |
Shares Outstanding 1473830016 | Shares Floating 1469538647 |
Percent Insiders 0.18 | Percent Institutions 92.47 |
Trailing PE 74.65 | Forward PE 32.26 | Enterprise Value 141886836720 | Price to Sales(TTM) 8.37 |
Enterprise Value to Revenue 8.92 | Enterprise Value to EBITDA 38.08 | Shares Outstanding 1473830016 | Shares Floating 1469538647 |
Percent Insiders 0.18 | Percent Institutions 92.47 |
Analyst Ratings
Rating 4.45 | Target Price 61.18 | Buy 8 |
Strong Buy 20 | Hold 5 | Sell - |
Strong Sell - |
Rating 4.45 | Target Price 61.18 | Buy 8 | Strong Buy 20 |
Hold 5 | Sell - | Strong Sell - |
AI Summarization
Boston Scientific Corp. (BSX): A Comprehensive Overview
Company Profile:
Detailed History and Background:
Boston Scientific Corporation (BSX) is a global medical device company founded in 1979. They started by developing and manufacturing angioplasty balloon catheters for the treatment of coronary artery disease. Over the years, BSX has expanded its portfolio through organic growth and acquisitions, becoming a leading player in various medical specialties, including:
- Interventional Cardiology: Devices for treating heart disease, such as stents, balloons, and closure devices.
- Cardiac Rhythm Management: Pacemakers, defibrillators, and cardiac resynchronization therapy devices.
- MedSurg: Endoscopes, surgical staplers, hernia repair products, and more.
- Neuromodulation: Spinal cord stimulation, deep brain stimulation, and other therapies for chronic pain and neurological disorders.
- Oncology: Devices for minimally invasive cancer treatment.
Core Business Areas:
BSX operates through four main business segments:
- Cardiovascular: Offers devices and solutions for treating heart disease, including coronary, peripheral, and structural heart conditions.
- Rhythm Management: Provides pacemakers, defibrillators, and cardiac resynchronization therapies.
- MedSurg: Focuses on devices and technologies for minimally invasive surgery, including endoscopy, hernia repair, and vascular access.
- Neuromodulation: Develops and markets neuromodulation therapies for chronic pain, movement disorders, and other neurological conditions.
Leadership Team and Corporate Structure:
The company is led by CEO and President Mike Mahoney, CFO Jeff Capello, and a team of experienced executives. BSX operates in over 100 countries with a global workforce of approximately 40,000 employees.
Top Products and Market Share:
Top Products:
- Stents: DES (Drug Eluting Stent) and BMS (Bare Metal Stent)
- Mitral and Tricuspid Repair: TEER, TriClip, PASCAL
- Peripheral Interventions: Embolization coils, drug-coated balloons
- Pacemakers: Emblem, INCEPTA, ACUITY
- Defibrillators: EMBLEM MRI S-ICD, INCEPTA MRI S-ICD
- Endoscopy: PyloriX, SpyGlass DS
- Neurostimulation: Spinal Cord Stimulator (SCS), Deep Brain Stimulation (DBS)
Market Share:
- Global share of the coronary stent market: 20%
- Global market leader in transcatheter mitral valve repair
- US market leader in WATCHMAN left atrial appendage closure
- Significant market share in various other segments including pacemakers, defibrillators, and endoscopy
Product Performance and Market Reception:
BSX's products are generally well-regarded by medical professionals and patients. The company has a strong track record of innovation and product development, consistently introducing new and improved technologies.
Total Addressable Market:
The global medical device market is estimated to be worth over $500 billion, with the cardiovascular device market alone valued at over $50 billion. BSX operates in several high-growth segments within this market, providing a substantial growth opportunity.
Financial Performance:
Recent Financial Statements:
- Revenue: $13.41 billion (2022)
- Net Income: $2.49 billion (2022)
- Gross Profit Margin: 74% (2022)
- Operating Margin: 30% (2022)
- Earnings per Share (EPS): $4.17 (2022)
Year-over-Year Performance:
- Revenue has grown at a CAGR of 8% over the past five years.
- Net income has grown at a CAGR of 10% over the past five years.
- EPS has grown at a CAGR of 12% over the past five years.
Cash Flow and Balance Sheet:
- Strong cash flow generation, with operating cash flow of $3.3 billion in 2022.
- Relatively low debt levels, with a debt-to-equity ratio of 0.5.
Dividends and Shareholder Returns:
Dividend History:
- BSX has a history of paying dividends, with a current annual dividend yield of 0.66%.
- The company has increased its dividend every year for the past 10 years.
Shareholder Returns:
- Total shareholder returns over the past 5 years have been over 100%.
Growth Trajectory:
Historical Growth:
- BSX has experienced consistent revenue and earnings growth over the past 5 to 10 years.
Future Growth Projections:
- Analysts expect the company to continue growing at a moderate pace in the coming years.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boston Scientific Corp
Exchange | NYSE | Headquaters | Marlborough, MA, United States |
IPO Launch date | 1992-05-18 | Chairman, President & CEO | Mr. Michael F. Mahoney |
Sector | Healthcare | Website | https://www.bostonscientific.com |
Industry | Medical Devices | Full time employees | 48000 |
Headquaters | Marlborough, MA, United States | ||
Chairman, President & CEO | Mr. Michael F. Mahoney | ||
Website | https://www.bostonscientific.com | ||
Website | https://www.bostonscientific.com | ||
Full time employees | 48000 |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.